-
专业包装 正品保证
-
快乐服务 售后无忧
-
会员特权 优惠不断
-
个人信息 严格保护
| 别名: | |||
|---|---|---|---|
| 储存条件: | -20℃ | ||
|
| 货号 | 规格 | 可用库存 | 销售价(RMB) | 您的折扣价(RMB) | 购买数量 |
|---|
| 熔点: | |
|---|---|
| 密度: | |
| 储存条件: | -20℃ |
Human VEGF165-coupled Magnetic Beads
The Human VEGF165-coupled Magnetic Beads is produced by coupling biotinylated human VEGF165 protein to streptavidin-conjugated magnetic beads. The pre-coupled beads are ready to use for capturing anti-VEGF165 antibody or VEGFR2/KDR protein from your sample with high specificity. The uniform size and large surface-to-volume ratio of the beads ensure highly efficent immunocapture in a simple, fast and convenient workflow with high reproducibilty of data.
This product is intended for immunocapture, biopanning and flow cytometry. This is a non-sterile product.
See Certificate of Analysis (CoA) for detailed instruction.
Upon receipt, please store the Beads at -20℃. The shelf life is 1 year at -20 ℃.
Please avoid more than 3 freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
Antibody Purification:
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.
Immobilized 31.6 μg VEGF165 protein/1mg beads can bind Anti-VEGF Antibody with an EC50 of 0.7726 μg/mL (QC tested).
Protocol
Accelerated stability test. After placing the lyophilized beads at 37℃ for 7 days, binding activity between the Human VEGF165-coupled Magnetic Beads and Bevacizumab showed little deviation from the unaccelerated sample (%RSD<10%). Data were measured on day 0, 3, 7 respectively.
Protocol
Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the Human VEGF165-coupled Magnetic Beadsand Bevacizumab showed little deviation from the unfree-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.
